Caribou Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Caribou Biosciences, Inc.
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
A US decision to grant a CRISPR Cas9 patent to The Broad Institute lifts Editas but adds uncertainty to the IP estate of Intellia and CRISPR Therapeutics.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools